CJMB News & Events

Callan JMB announced it has signed a strategic teaming agreement with Biostax Corp d/b/a Attune Biotech, a clinical-stage biopharmaceutical company with a diversified therapeutic pipeline. Callan JMB will serve as independent third-party overseer of Attune 's manufacturing, quality assurance and control, and deployment operations. Under the agreement, Callan JMB will provide federal oversight services, including manufacturing quality assurance and independent batch record review, Biomedical Advanced Research and Development Authority contract compliance, Food and Drug Administration audit readiness and mock inspections, milestone tracking, and federal reporting, supply chain governance and supplier qualification, and Strategic National Stockpile deployment coordination.

Callan JMB announced a comprehensive strategic realignment to address the critical infrastructure gap in the global distribution of GLP-1 medications. As the pharmaceutical industry faces a logistics bottleneck due to the meteoric rise of weight-management and diabetes treatments such as Ozempic, Wegovy, and Mounjaro, Callan JMB is positioning its proprietary cold-chain technology to become the primary "last-mile" fulfillment partner for large-scale telehealth and pharmaceutical distributors. The distribution of GLP-1 agonists requires an unbroken cold chain between 2 degrees C and 8 degrees C. Any deviation renders these high-value biological drugs ineffective. Callan JMB's strategic expansion includes: Texas cGMP Hub Integration: The company has officially begun the phase-one retrofitting of its Texas facility to host high-capacity pharmaceutical-grade refrigeration units. This follows the preliminary agreement to host advanced oral drug delivery manufacturing equipment, creating a dual-purpose hub for both production support and cold-chain fulfillment. Next-Gen Thermal Packaging: CJMB is deploying a new line of proprietary, eco-friendly thermal shippers equipped with real-time IoT sensors. These sensors provide cloud-based temperature monitoring, ensuring zero-excursion delivery-a mandatory requirement for high-tier pharmaceutical contracts. Scalable Fulfillment for Telehealth: With the surge in direct-to-consumer pharmaceutical platforms, CJMB is optimizing its 3PL software to integrate directly with telehealth provider APIs, allowing for seamless, temperature-guaranteed home delivery.

Callan JMB announced that it has entered a preliminary agreement with the maker of an oral drug delivery system to install its innovative manufacturing equipment in Callan JMB's cGMP facility in Texas, while the two companies negotiate operational agreements. "We are excited about this new partnership and the opportunities that installing the client's manufacturing technology at our facility will open up for safe and effective oral drug delivery," said Wayne Williams, CEO of Callan JMB. "This agreement is in line with our goals for expansion into ground-breaking healthcare and wellness technologies."

Callan JMB announced the expansion of its reclamation operations into the food sampling industry. This move is part of Callan JMB's multi-variant strategic growth initiative designed to extend its proven compliance-driven model into adjacent, high-growth markets. While most food sampling programs focus on reach and trial, few have standardized sustainable packaging or waste-reduction practices - creating an accountability gap. As brands face increasing pressure to cut waste and measure impact, the sampling channel presents a clear opportunity for logistics partners that deliver sustainability, compliance, and traceability.